Table 3.
Exponentiated regression coefficient indicating percent change in log immunological parameters from baseline after 6 and 12 months of combination antiretroviral therapy from latent growth-curve modeling (n = 20).
| 6 months |
12 months |
|
|---|---|---|
| Immune parameter outcome | Exp b (95% CI)a | Exp b (95% CI)a |
| NK cell activation/function | ||
| NK cell (% CD69+) | 0.89 (0.85,0.93) | 0.80 (0.73,0.87) |
| NK cell (% HLA DR+/CD38+) | 0.94 (0.88,1.01) | 0.89 (0.76,1.02) |
| CD56dim FcRγ− NK cells | 0.94 (0.88,0.99) | 0.88 (0.77,0.99) |
| T cell activation | ||
| CD4+ (% HLA DR+/CD38+) | 0.77 (0.73,0.82) | 0.60 (0.53,0.67) |
| CD8+ (% HLA DR+/CD38+) | 0.50 (0.41,0.60) | 0.30 (0.21,0.39) |
| Monocyte subsets | ||
| % Classical monocytes | 1.36 (1.23,1.51) | 1.85 (1.54,2.38) |
| % Intermediate monocytes | 0.56 (0.46,0.66) | 0.47 (0.38,0.56) |
| % Non-classical monocytes | 0.74 (0.64,0.84) | 0.55 (0.40,0.70) |
aExponentiated regression coefficients (Exp b) and 95% confidence intervals (95% CI) from non-linear combined (i.e., linear and quadratic terms) effect estimation based on log-normal latent growth-curve models—coefficient (Exp b) represents the ratio of expected geometric mean difference in a marker for a specific length of time taking account of the functional form of the effect of time (i.e., % change in a marker per specified time-period). Ratios <1 indicate a percent decrease. Values in bold indicate marker levels exhibiting significant change over-time.